J. Vincent

发表

Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial

M. Böhm, B. Pitt, F. Zannad, 2021, Clinical Research in Cardiology.

Effects of Food on a Gastrically Degraded Drug: Azithromycin Fast-Dissolving Gelatin Capsules and HPMC Capsules

W. Curatolo, G. Foulds, Ping Liu, 2011, Pharmaceutical Research.

Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms

J. McMurray, H. Krum, B. Pitt, 2014, Heart.

Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate

J. McMurray, D. J. Veldhuisen, K. Swedberg, 2019, Clinical Research in Cardiology.

Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia

S. Solomon, J. McMurray, K. Swedberg, 2017, European journal of heart failure.

Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial

J. McMurray, K. Swedberg, S. Pocock, 2021, Circulation. Heart failure.

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses

E. Burgess, J. Vincent, P. Abreu, 2018, Vascular Health and Risk Management.

Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Effic

B. Pitt, P. Rossignol, J. Ketelslegers, 2017, International journal of cardiology.

Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.

B. Pitt, F. Zannad, S. Carillo, 2014, Archives of cardiovascular diseases.

Eplerenone in patients with systolic heart failure and mild symptoms.

J. McMurray, K. Swedberg, S. Pocock, 2011, The New England journal of medicine.

Estimated Long-Term Survival With Eplerenone.

J. McMurray, B. Pitt, F. Zannad, 2019, Journal of the American College of Cardiology.

Eplerenone and new‐onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF)

J. McMurray, D. J. Veldhuisen, K. Swedberg, 2012, European journal of heart failure.

Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Study

B. Pitt, F. Zannad, P. Rossignol, 2009, Circulation.

Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study.

M. Flather, B. Pitt, F. Zannad, 2014, European heart journal.

Type 2 Diabetes: Progress Made but Still a Long Road to Travel to Reduce Disease Burden

S. Terra, J. Vincent, SG Terra, 2015, Clinical pharmacology and therapeutics.

Response to “The Failing Right Heart: The Neglected Ventricle?”

J. Vincent, 2014, Clinical pharmacology and therapeutics.

Eplerenone versus placebo renal function stratified dose comparisons in the EMPHASIS-HF trial

J. McMurray, P. Rossignol, J. Ferreira, 2019 .

Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial

M. Flather, B. Pitt, F. Zannad, 2018, Clinical Research in Cardiology.

SAFETY AND EFFICACY OF EPLERENONE IN PATIENTS AT HIGH RISK FOR HYPERKALEMIA AND/OR WORSENING RENAL FUNCTION. ANALYSES OF THE EMPHASIS-HF STUDY SUBGROUPS (EPLERENONE IN MILD PATIENTS HOSPITALIZATION AND SURVIVAL STUDY IN HEART FAILURE)

J. McMurray, K. Swedberg, S. Pocock, 2014 .

Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple

J. Vincent, 2018, Clinical pharmacology and therapeutics.

H016 Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the ephesus study

B. Pitt, F. Zannad, P. Rossignol, 2009 .

Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.

H. White, M. Gheorghiade, H. Krum, 2005, Journal of the American College of Cardiology.

Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study.

J. McMurray, K. Swedberg, H. Krum, 2012, Journal of the American College of Cardiology.

353 Eplerenone benefit at 30 days in high‐risk subgroups in the EPHESUS trial

D. J. Veldhuisen, H. Krum, B. Pitt, 2005 .

Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study

M. Flather, B. Pitt, F. Zannad, 2017, Clinical Research in Cardiology.

Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF)

J. McMurray, D. J. Veldhuisen, K. Swedberg, 2010, European journal of heart failure.

Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations

J. McMurray, K. Swedberg, S. Pocock, 2012, Circulation.

Rare Diseases: The Bane of Modern Society and the Quest for Cures

N. Azie, J. Vincent, John Vincent, 2012, Clinical pharmacology and therapeutics.

Heart Failure: A Disease Complex with Challenging Therapeutics

J. Vincent, 2013, Clinical pharmacology and therapeutics.

Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns

Tariq Ahmad, Patrick Rossignol, Bertram Pitt, 2018, Circulation. Heart failure.

Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS‐HF study

J. McMurray, K. Swedberg, H. Krum, 2016, European journal of heart failure.

Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.

J. McMurray, K. Swedberg, S. Pocock, 2015, European heart journal.

Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Study

J. McMurray, H. Krum, B. Pitt, 2014 .

Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).

J. McMurray, K. Swedberg, S. Pocock, 2013, Journal of the American College of Cardiology.

The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.

J. McMurray, K. Swedberg, S. Pocock, 2013, European heart journal.

Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study

J. McMurray, K. Swedberg, S. Pocock, 2013, Circulation. Heart failure.

Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial †

G. Filippatos, B. Pitt, F. Zannad, 2009, European journal of heart failure.

Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function

J. McMurray, D. J. Veldhuisen, K. Swedberg, 2022 .

Association of obesity and survival in systolic heart failure after acute myocardial infarction: potential confounding by age

S. Anker, B. Pitt, Audrey H. Wu, 2010, European journal of heart failure.

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial

J. McMurray, K. Swedberg, S. Pocock, 2019, European journal of heart failure.

Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial.

J. McMurray, K. Swedberg, M. Böhm, 2020, Journal of hypertension.

Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.

C. Ballantyne, H. Bays, A. Cropp, 2015, The American journal of cardiology.

=EFFICACY AND SAFETY OF BOCOCIZUMAB (RN316/PF-04950615), A MONOCLONAL ANTIBODY AGAINST PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN STATIN-TREATED HYPERCHOLESTEROLEMIC SUBJECTS: RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY (NCT: 01592240)

C. Ballantyne, H. Bays, A. Cropp, 2014 .

World Health and Bioterrorism

J. Vincent, 2009, Clinical pharmacology and therapeutics.

Biostatistics and Pharmacometrics: Quantitative Sciences to Propel Drug Development Forward

B P Smith, J Vincent, J. Vincent, 2010, Clinical pharmacology and therapeutics.

Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS‐HF)

J. McMurray, K. Swedberg, S. Pocock, 2015, European journal of heart failure.

Reduces Mortality 0 Days After Randomization Following cute Myocardial Infarction in Patients With eft Ventricular Systolic Dysfunction and Heart Failure

H. White, M. Gheorghiade, H. Krum, 2016 .

plerenone Reduces Mortality 0 Days After Randomization Following cute Myocardial Infarction in Patients With eft Ventricular Systolic Dysfunction and Heart Failure

H. White, M. Gheorghiade, H. Krum, 2005 .

Drugs and the Kidneys: Clinical Pharmacology Perspectives

J. Vincent, 2017, Clinical pharmacology and therapeutics.

Reducing Elevated Plasma LDL Cholesterol: The Central Role of the LDL Receptor

J. Vincent, John Vincent, 2014, Clinical pharmacology and therapeutics.

The Paradox of Obesity and Cardiovascular Disease Risk: Time to Change Labels

J. Vincent, 2011, Clinical pharmacology and therapeutics.

Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial.

B. Pitt, F. Zannad, P. Rossignol, 2022, European heart journal. Acute cardiovascular care.

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms : Analysis of Repeat Hospitalizations

J. McMurray, D. J. Veldhuisen, K. Swedberg, 2012 .

Eplerenone in patients with systolic heart failure and mild symptoms.

J. McMurray, K. Swedberg, S. Pocock, 2011, The New England journal of medicine.

F. Zannad, J. Michel, P. Rossignol, 2017, International journal of cardiology.

J. McMurray, K. Swedberg, S. Pocock, 2013, Journal of the American College of Cardiology.

Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF)

J. McMurray, D. J. Veldhuisen, K. Swedberg, 2010, European journal of heart failure.

Eplerenone and new‐onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF)

J. McMurray, D. J. Veldhuisen, K. Swedberg, 2012, European journal of heart failure.

Eplerenone in patients with systolic heart failure and mild symptoms: Analysis of repeat hospitalizations.

D. J. Veldhuisen, K. Swedberg, J. McMurray, 2015 .

Heart Failure Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms Analysis of Repeat Hospitalizations

K. Swedberg, H. Krum, F. Zannad, 2012 .

My Cancer Health Manager

Marivic S. Tangkeko, J. Vincent, C. Chavez, 2014 .